BPH Diagnosis: How Doctors Diagnose Enlarged Prostate

Diagnostic overview – the step-by-step process

Diagnosing BPH involves a systematic approach to confirm prostate enlargement, assess symptom severity, rule out other causes (cancer, infection, stricture), and evaluate for complications. The evaluation typically proceeds from simple, non-invasive tests to more complex procedures when needed.

Basic evaluation (all patients):

• Medical history and symptom questionnaire (IPSS)
• Digital Rectal Exam (DRE)
• Urinalysis
• PSA test (after discussion of risks/benefits)

Recommended tests (most patients):

• Uroflowmetry
• Post-void residual (PVR) measurement

Advanced tests (selected patients):

• Cystoscopy
• Imaging (transrectal ultrasound, MRI)
• Urodynamics

Medical history and symptom assessment (IPSS)

The evaluation begins with a detailed medical history:

• Symptom history: Onset, duration, and severity of urinary symptoms (frequency, urgency, weak stream, nocturia, hesitancy).
• IPSS questionnaire: The 7-question International Prostate Symptom Score (0-35) quantifies symptom severity. A score of ≥8 with bother indicates treatment candidacy.
• Quality of life (QoL) question: Measures how bothered the patient is (0=delighted, 6=terrible). QoL ≥4 often prompts treatment.
• Medical conditions: Diabetes, neurologic disease, prior pelvic surgery, urethral stricture.
• Medications: Decongestants, antihistamines, diuretics, calcium channel blockers – can worsen symptoms.
• Fluid intake: Caffeine, alcohol, excessive evening fluids – contribute to nocturia.

Digital Rectal Exam (DRE)

The DRE is a physical examination where the doctor inserts a gloved, lubricated finger into the rectum to feel the prostate.

What the doctor assesses:

• Size: Estimated in grams (normal 15-20g; BPH often 30-100+g).
• Symmetry: BPH causes symmetric enlargement; asymmetry suggests cancer.
• Consistency: BPH feels smooth and rubbery; cancer feels hard and nodular.
• Median sulcus: Groove between lobes – may be obliterated in BPH.
• Tenderness: Suggests prostatitis, not BPH.

Limitations of DRE:

• Subjective – varies between examiners
• Cannot assess median lobe enlargement (which can cause obstruction)
• Does not measure prostate volume accurately

PSA test – role in BPH and ruling out cancer

PSA (prostate-specific antigen) is a blood test used primarily for prostate cancer screening, but it also provides information about BPH.

PSA in BPH:

• BPH causes mild PSA elevation (typically 4-10 ng/mL) because larger prostates produce more PSA.
• PSA density (PSA divided by prostate volume) helps distinguish BPH from cancer (PSAD >0.15 suggests cancer).
• Men on 5-ARIs (finasteride, dutasteride) have PSA levels reduced by ~50% after 6 months.

When PSA suggests further evaluation:

• PSA >10 ng/mL – high cancer risk, biopsy often indicated.
• PSA velocity >0.75 ng/mL/year – concerning for cancer.
• Abnormal free PSA (<10-15%) – increased cancer risk.

Urinalysis and urine culture

Urinalysis is a simple, non-invasive test that rules out other causes of urinary symptoms:

• Urinary tract infection (UTI): White blood cells, nitrites, bacteria – treat with antibiotics before BPH evaluation.
• Hematuria (blood in urine): Can be caused by BPH (engorged vessels), but also bladder cancer or stones – requires further evaluation.
• Glycosuria (glucose in urine): Suggests diabetes, which can cause frequency and nocturia.

If urinalysis suggests infection, a urine culture should be sent to identify the organism and antibiotic sensitivities.

Uroflowmetry – measuring urine flow rate

Uroflowmetry is a simple, non-invasive test where the patient urinates into a device that measures urine flow rate over time.

Key measurements:

• Qmax (peak flow rate): The maximum flow rate (mL/s). Normal is >15 mL/s. Qmax <10 mL/s suggests significant obstruction.
• Average flow rate: Less useful than Qmax.
• Flow pattern: A flat, prolonged curve suggests obstruction; a normal bell-shaped curve suggests no obstruction.
• Voided volume: Should be >150 mL for accurate interpretation.

Limitations:

• Can be affected by patient effort, bladder volume, and anxiety.
• Cannot distinguish between obstruction and poor bladder contraction (underactivity).
• Should be repeated at least twice for accuracy.

Post-void residual (PVR) – measuring leftover urine

PVR measures how much urine remains in the bladder after urination. It is performed using a bladder ultrasound (non-invasive).

• Normal: <50 mL
• Mild elevation: 50-100 mL – may be normal in older men
• Moderate elevation: 100-250 mL – suggests significant obstruction or poor bladder emptying
• Severe elevation: >250 mL – chronic retention, risk of complications

Clinical significance:

• High PVR is a risk factor for recurrent UTIs, bladder stones, and renal impairment.
• PVR >300 mL may indicate need for surgical intervention.
• Very high PVR (>500 mL) indicates chronic urinary retention – can damage kidneys.

Cystoscopy – visual examination

Cystoscopy involves passing a thin, flexible camera through the urethra into the bladder to visualise the prostate and bladder.

What cystoscopy reveals:

• Prostate size and shape: Degree of obstruction, median lobe enlargement, bladder neck contracture.
• Bladder changes: Trabeculation (muscle thickening from obstruction), cellules, diverticula, stones, or tumours.
• Urethral stricture: Narrowing of the urethra that mimics BPH symptoms.

When is cystoscopy indicated?

• Before surgical treatment (TURP, HoLEP) to plan the procedure
• When hematuria is present (to rule out bladder cancer)
• When symptoms are atypical or refractory to treatment
• When urethral stricture is suspected

Imaging studies – ultrasound, MRI

Transrectal Ultrasound (TRUS):

• Measures prostate volume accurately (using the ellipsoid formula).
• Calculates PSA density (PSA/volume) – helps distinguish BPH from cancer.
• Guides prostate biopsy if cancer is suspected.

Transabdominal Ultrasound:

• Measures PVR and bladder wall thickness.
• Can estimate prostate volume (less accurate than TRUS).
• Evaluates hydronephrosis (kidney swelling from chronic retention).

MRI (mpMRI):

• Most accurate for prostate volume and cancer detection.
• Not routine for BPH – reserved when cancer is suspected (elevated PSA, abnormal DRE).

Urodynamics – for complex cases

Urodynamics is the gold standard for diagnosing bladder outlet obstruction (BOO) and distinguishing it from bladder underactivity.

When is urodynamics indicated?

• Prior to surgery in men with borderline obstruction (e.g., Qmax 10-15 mL/L)
• Neurologic conditions (Parkinson's, stroke, spinal cord injury)
• Previous failed BPH surgery
• Suspected bladder underactivity (poor contraction) vs. obstruction

Key urodynamic findings in BPH:

• Bladder outlet obstruction (BOO): High detrusor pressure with low flow rate (pressure-flow study).
• Detrusor overactivity (DO): Involuntary bladder contractions – may persist after BPH treatment.

When to see a urologist – red flags

A primary care doctor can initiate BPH evaluation, but referral to a urologist is indicated for:

• IPSS ≥8 with bothersome symptoms (treatment discussion)
• Elevated PSA or abnormal DRE (rule out cancer)
• Hematuria (blood in urine)
• Recurrent UTIs
• Bladder stones
• Acute or chronic urinary retention (PVR >250 mL)
• Renal impairment (elevated creatinine)
• Failed medical therapy
• Considering surgical treatment

Interactive FAQ – BPH diagnosis

---

Disclaimer: This information is for educational purposes. If you have urinary symptoms, see a urologist at Vivekananda Hospital for proper evaluation and diagnosis.